What is CVS’s Current Revenue & EBITDA Breakdown?
CVS derives >60% of its revenue from PBM, but Prescription Drugs is a more profitable business
Have more questions about CVS Health (NYSE:CVS)? Click on the links below:
- What’s CVS’s Fundamental Value Based on Expected 2016 Results?
- By How Much Can CVS’s Revenue & EBITDA Grow In The Next 5 Years: Trefis Estimate
- By What Percentage Did CVS’s Revenue & EBITDA Grow In The Last 5 Years?
- Higher Medical Costs Likely Weighed On CVS Health’s Q1 Earnings
- Should You Pick CVS Stock At $75 After A 6% Fall This Year?
- Is CVS Health Stock Undervalued At $70?
- Will CVS Health Stock Recover To Its Pre-Inflation Shock Highs of $110?
- Higher Costs To Weigh On CVS Health’s Q2?
- Should You Buy CVS Stock At $70?
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our detailed analysis for CVS Health
See More at Trefis | View Interactive Institutional Research (Powered by Trefis) Get Trefis Technology